Methods and compositions for inhibiting cell proliferative disorders
AssigneesSugen, Inc., Yissum Research Development Company of the Hebrew University of Jerusalem
InventorsHui Chen, Aviv Gazit, Alexander Levitzki, Klaus Peter Hirth, Elaina Mann, Laura K. Shawver, Jianming Tsai, Peng Cho Tang
Life of this patent
Estimating the term…
Abstract
The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers charcterized by over-activity or inappropriate activity HER2 or EGFR.
Claims17
A compound having the chemical formula:
- ##STR22## or a pharmaceutically acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.3 are each independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, halogen, hydrogen, OH, amine, thioether, SH and NH.sub.2 ;
- R.sub.6 is selected from the group consisting of alkyl, alkenyl, alkynyl, alkylaryl, halogen, hydrogen, amine, thioether, SH and NH.sub.2 ;
- and
- X.sub.1, X.sub.2, X.sub.3, X.sub.4, and X.sub.5 are each independently selected from the group consisting of hydrogen, halogen, trihalomethyl, alkyl, alkenyl, alkynyl, alkoxy, and NO.sub.2, provided that at least one of X.sub.1, X.sub.2, X.sub.3, X.sub.4, and X.sub.5 is a trihalomethyl.
A compound having the chemical formula:
- ##STR23## or a pharmaceutically acceptable salt thereof, wherein R.sub.1, R.sub.2, and R.sub.3 are each independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, halogen, hydrogen, OH, amine, thioether, SH and NH.sub.2 ;
- R.sub.6 is hydrogen;
- and
- X.sub.1, X.sub.2, X.sub.3, X.sub.4, and X.sub.5 are each independently selected from the group consisting of hydrogen, halogen, trihalomethyl, alkyl, alkenyl, alkynyl, alkoxy, and NO.sub.2, provided that at least one of X.sub.1, X.sub.2, X.sub.3, X.sub.4, and X.sub.5 is a trihalomethyl.
The compound (E)-3-(3,5-diisopropyl-4-hydroxyphenyl)-2-(4-trifluoromethyl) phenylaminocarbonyl!acrylonitrile or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.